Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

ed "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," in the online version of the journal Clinical Cancer Research that showed that 100% of 14 evaluable patients were stable disease or better (7 partial responses, and 7 stable disease); - A poster presentation at the American Association for Cancer Research's 101st Annual Meeting in Washington, DC entitled "Reovirus replication in ovarian and peritoneal tumors after intravenous administration," covering correlative results from a Phase 1/2 study with reovirus in patients with ovarian, primary peritoneal and fallopian tube carcinoma, sponsored by the National Cancer Institute under its Clinical Trials Agreement with Oncolytics;

Clinical Program

        -  Opening of enrollment in the Phase 3 trial examining REOLYSIN in
           combination with paclitaxel and carboplatin in patients with
           platinum-refractory head and neck cancers;
        -  Receipt of a No Objection Letter from Health Canada to conduct its
           Phase 3 trial examining REOLYSIN in combination with paclitaxel
           and carboplatin in patients with platinum-refractory head and neck
           cancers;
        -  Receipt of approval from the Belgian Federal Agency for Medicines
           and Health Products (FAMHP) to conduct its Phase 3 trial examining
           REOLYSIN in combination with paclitaxel and carboplatin in
           patients with platinum-refractory head and neck cancers;
        -  Start of enrollment in a U.S. Phase 2 clinical trial using
           intravenous administration of REOLYSIN in combination with
           gemcitabine (Gemzar(R)) in patients with advanced pancreatic
           cancer at the Cancer Therapy & Research C
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 SRI International has ... the National Institute of Allergy and Infectious Diseases (NIAID), ... preclinical development of potential therapies for HIV infection and ... treat HIV and AIDS and the complications and opportunistic ... for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... 1000 balances – 4 steps – One ... needs and expertly narrows down the mass of product ... even terminals. , First, select the working environment, ... readability instead) and define the accuracy – it’s really ... down the list to models that fit best with ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... 28 Beckman Coulter, Inc. (NYSE: ... Directors declared a quarterly dividend payout of seventeen ... payable on May 22, 2009 to all stockholders ... payout represents the 80th consecutive, quarterly payout of ...
... ANGELES, April 28 MMR Information Systems (OTC ... subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") provides Web-based consumer-controlled ... ) and electronic safe deposit box storage solutions ... free Personal Health Record and free surgical masks ...
... its financial results for the first quarter of fiscal 2009 ... will be hosted by management at 11 a.m. ET following ... on the company,s Web site, www.usoncology.com , ... announcement. US/Canada Dial-in #: (877) 615-1716 , Conference ...
Cached Biology Technology:MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 2MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 3MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic 4US Oncology to Report 2009 First Quarter Operating Results 2
(Date:7/24/2014)... current biodiversity, the product of 3.5 billion years of ... history of life. But it may be reaching a ... literature and analysis of data published in Science ... loss and decline of animals is contributing to what ... sixth mass biological extinction event. , Since 1500, more ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... and one of the most species richness biome of ... current levels of diversity might be still underestimated. In ... the description of new endemic species of this biome ... of samples for DNA analysis. , Using a ... analysis, researchers from the University of Richmond ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A tiny new species of frog from Brazil with a heroic name 2
... The Federation of American Societies for Experimental Biology ... Research Conference (SRC): Mobile DNA in Mammalian Genomes. ... forces shaping the structure and altering functions within mammalian ... conference will explore the explosion of data from high ...
... Societies for Experimental Biology (FASEB) announces the opening ... Gastrointestinal Tract XV: Epithelia, Microbes, Inflammation and Cancer. ... and Reversible Acetylation in Signaling and Disease is ... biological functions of reversible protein acetylation are explored ...
... University chemistry professor has begun imbedding magnetic nanoparticles ... more than 40,000 Americans must replace their knee ... Samia, an assistant professor who specializes in metallic ... Science Foundation-CAREER grant to create new materials and ...
Cached Biology News:New effort to find why replacement hips and knees go bad 2
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... Anti-HMGN2/HMG-17 Immunogen : Recombinant ... pH7.4, 5mg/ml BSA, 0.15M NaCl, ... addition of glycerol to 30% ... immunoblot on acid extracts of ...
... Assay, 96 wells. ELISA.Specific for total MMP-3: ... No cross-reactivity with MMP-1, -2, -9. Range: ... with cell culture supernatant, serum, plasma and ... -30 C. Category: Drug Screening & ...
Biology Products: